The Food and Drug Administration recently approved a new low dose version of Orexo's treatment for opioid dependence.
The drug, called Zubsolv, is a formulation of buprenorphine — a partial opioid agonist used to suppress withdrawal symptoms and opioid cravings — and naloxone, an opioid overdose antidote.
"The new dosage has been developed in response to physician requests to be able to tailor dosing as they taper patients and ultimately provide a lower minimally effective maintenance dose," said Nikolaj Sørensen, president and CEO of Uppsala, Sweden-based Orexo.
The new low dose version of Zubsolv marks the sixth and final dosage strength the company will offer. It will hit the shelves of U.S. pharmacies in early 2017.
More articles on supply chain:
FedEx to open new Ohio distribution center in 2017
Insmed buys AstraZeneca's respiratory drug for $150M: 5 things to know
Novartis restructures research unit, sheds 175 jobs: 4 things to know